# Aphea.Bio Financial Model Aphea.Bio is a Belgian ag-biotech company developing and commercialising microbial biologicals (biostimulants, biofungicides, bioherbicides, bioinsecticides) for row crops, targeting yield improvement and reduced synthetic input use. - Canonical: https://finamodel.com/startups/apheabio - Excel download: https://finamodel.com/startup-models/apheabio.xlsx - Category: Biotech/Pharma - Model type: Biotech rNPV - Funding round: Series C - Funding: €70M - Founded: 2023 - Geography: Europe primary (EU climatic zones explicitly cited); US expansion planned from ~2024 onwards per product roadmap [DECK, slide 9]. - Customer: B2B ## About the company Aphea.Bio develops microbial biologicals intended to reduce synthetic fertiliser and crop-protection use. Its biostimulants support nutrient efficiency and yield, while biocontrol products address fungi, weeds, and insects across wheat, barley, maize, fruit, and vegetables. The first wheat and maize nutrient-use-efficiency products were planned for launch in 2024 and 2025, with 30 market introductions from 16 active substances targeted through 2031. A strain library of more than 100,000 candidates feeds a four-phase R&D funnel, supported by a broad patent portfolio. Field trials showed wheat yield gains of 2.7% to 6.3% and maize biomass gains of 5% to 22% under reduced fertiliser. The company was pre-revenue, targeting first sales in 2023 and break-even in 2027. The model should forecast regulatory timing, acres treated, product price, distributor margin, manufacturing, trials, and adoption. ## What's included - 5-year monthly revenue build with stage-appropriate growth assumptions - Full P&L, headcount plan, and operating-expense schedule - Cash-flow statement, runway, and burn-rate tracking - Valuation via exit multiple with a DCF cross-check - Returns analysis with MOIC and IRR - Unit economics including CAC, LTV, payback, and cohort retention ## Product & value proposition - Microbial biologicals that replace or reduce synthetic fertilisers and chemical crop protection products. - Two product categories: **Biostimulants** (Nutrient Use Efficiency / yield, abiotic stress) and **Biocontrols** (fungicides, herbicides, insecticides). - Primary crops targeted: wheat, barley, maize, durum, hybrid wheat, fruit & vegetables. - Two lead products imminent at time of deck (May 2022): wheat NUE biostimulant (launching 2024, timeline slide 7) and maize NUE biostimulant (launching 2025, slide 8). - Claims yield increase of 2.7–6.3% on wheat and 5–22% on maize biomass under reduced fertiliser use. - Pipeline: 30 planned market introductions based on 16 distinct active substances, running through 2031. - High-throughput R&D platform: >100,000 strain library screened down to ≥1 strain per product via 4-phase funnel. - Broad patent portfolio cited as "major competitive advantage". - B-Corp certification targeted for 2023 alongside first sales. ## Revenue model Not explicitly stated in deck. Inferred from business model: - Product sales of registered biological crop-protection and nutrition products to farmers, presumably via agrochemical distributors / co-ops (standard ag-product distribution model). - Revenue recognised per product (SKU) per crop per geography; both EU and US markets planned. - No pricing per litre/ha or per-unit economics disclosed. - No licensing, royalty, or contract-manufacturing revenue mentioned. ## Traction & metrics - Series A raised: €7.7m (2017) - Series B raised: €19.8m (2021) - Headcount milestones (FTEs on timeline): 9 (2017) → 17 (2018) → 21 (2019) → 30 (2020) → 36 (2021) → 43 (2022) → 66 (2023 projected) → 78 (2026 projected) - Wheat biostimulant field-trial results (2019–2021): yield increase Mediterranean 2.7% / win rate 67%; South-East 4.2% / 100%; North-East 6.3% / 75% - Maize biostimulant field-trial results (2021): yield increase Maritime 5.0% / win rate 67%; Mediterranean 10.0% / 100%; North-East 22.0% / 100% - Regulatory submission of first product: 2022 milestone - First sales: targeted 2023 - Break-even: targeted 2027 - Revenue at time of deck: €0 (pre-revenue, regulatory submission phase) - no historical revenue figures shown. ## Competition / moat - Moat: proprietary >100,000-strain microbial library; broad patent portfolio; "untapped microbial space" positioning (novel organisms vs. existing biologicals); integrated high-throughput R&D platform combining multiple technologies. - Cost advantage: stringent CoGs focus on row crops (commodity-scale volumes). - Competitive landscape: not explicitly named. Broader framing positions company against conventional synthetic ag-inputs, not named biologicals competitors. - Team pedigree: prior employers include Bayer, BASF, Syngenta, Nufarm, Biotalys, Lallemand - relevant industry backgrounds. ## Team & funding ask / use of funds - CEO: Isabel Vercauteren, PhD Plant Biotechnology, ~20 yrs, ex-Bayer/DevGen - BD: Benoit Lixon, ~15 yrs, ex-Tessenderlo/Eastman - Portfolio & ESG: Inge Van Daele, PhD, ~10 yrs, ex-Biotalys/AgroSavfe - Finance: Geert Bossuyt, ~25 yrs, ex-Deutsche Bank/KBC - Research: Steven Vandenabeele, PhD Biotechnology, ~15 yrs, ex-BASF/Cropdesign - Strategy: Ralph Beckers, PhD Biology, ~30 yrs, ex-Nufarm/Syngenta - Development: Manuele Ricci, MSc Agronomy, ~35 yrs, ex-Lallemand/Bayer - Total joint experience: 150 years cited - **Funding ask: €50m (Series C)** - Use of proceeds: R&D Expenses & Capex 67% / Sales, Marketing & Regulatory 18% / G&A 15% - Potential exit flagged at 2027 milestone --- ## Recommended financial model **Archetype + why:** Pipeline-stage biotech / agri-biotech P&L model with probability-weighted revenue build. Closest archetype is a **pharma-style pipeline NPV + operating P&L** adapted for ag-biologicals: each of the 30 products is a discrete revenue stream with a launch year, ramp curve, and probability of success. This mirrors how the deck's own projections are constructed ("probability weighted"). A standard 3-statement model with a product-by-product revenue driver sheet is the right build. **Forecast horizon & granularity:** Annual, 2022–2033 (matches deck's own presentation). Monthly detail not warranted pre-revenue; switch to annual throughout. **Key drivers & assumptions:** *Revenue build (by product cohort):* - Number of products launched per year: per roadmap, first launch 2023/2024, ramping to 30 introductions through 2031 - Revenue ramp post-launch: Year 1–3 ramp (0%→30%→70%→100% of peak), typical for registered ag products with distributor onboarding lag - Probability weight per product by pipeline phase: Phase 1 ~25%, Phase 2 ~50%, Phase 3 ~75%, Phase 4 ~90% (standard biotech attrition; deck implies probability-weighted numbers) - Geographic split EU vs US: EU first, US lagging ~2 years per roadmap; US addressable market 1.5–2× EU given crop acres *Cost structure:* - R&D Expenses + Capex: ~67% of €50m raise = ~€33.5m over ~3–4 years; model as declining % of sales post-commercialisation - Sales, Marketing & Regulatory: 18% of raise = ~€9m over raise period; scale with product launches - G&A: 15% of raise = ~€7.5m, relatively fixed; grows with headcount - Headcount: From 43 (2022) → 66 (2023) → 78 (2026) per deck; further growth post-2026 to support 30-product portfolio - Break-even: targeted 2027 *Financing:* - Series A: €7.7m (2017) - Series B: €19.8m (2021) - Series C: €50m (2022, this raise) - No further dilutive raises modelled; exit scenario 2027 per deck hint **Scenarios (Base / Bull / Bear - which variables flex):** - **Base:** Pipeline attrition per phase probabilities above; EU revenue at midpoint; 35% gross margin at first launch, expanding to 55% by 2030. - **Bull:** Higher win rates (slide 7–8 win rates are already strong at 67–100%), faster regulatory timelines, US market opens on schedule 2024–2025; all 30 products launch. - **Bear:** Regulatory delays push first wheat launch to 2025; 40% of pipeline fails to reach market; US delayed to 2027+; margin pressure from CRO/manufacturing scale-up costs. - Key flex variables: product count reaching market, revenue/product at maturity, gross margin trajectory, year of breakeven. **Required sheets / outputs:** 1. **Assumptions** - all drivers centralised; switches for Base/Bull/Bear 2. **Pipeline** - product-by-product table: launch year, target market (EU/US), probability weight, peak revenue, ramp schedule → annual revenue per product 3. **P&L** - Revenue (sum of pipeline), CoGS, Gross Profit, R&D, S&M&Regulatory, G&A, EBITDA, D&A, EBIT, net (simplified; no tax benefit until profitable) 4. **Cash Flow** - Operating CF, Capex (fermentation/formulation scale-up), net burn, cumulative cash; must reconcile to "cumulative cash" curve shown on slide 10 5. **Balance Sheet** - simplified (cash, intangibles/IP, debt if any) 6. **Funding & Runway** - Series C €50m drawdown, monthly burn vs. projected first revenues, runway to breakeven 7. **Dashboard** - KPI summary: products launched by year, revenue, EBITDA, cumulative cash, headcount ## Frequently asked questions ### Is the Aphea.Bio financial model free? Yes. The Aphea.Bio model is a free Excel download with live formulas. ### Can I change the assumptions? Yes. The workbook is editable and its live formulas recalculate when assumptions change.